Literature DB >> 28002661

Potential Applications of the National Institute of Mental Health's Research Domain Criteria (RDoC) to Clinical Psychiatric Practice: How RDoC Might Be Used in Assessment, Diagnostic Processes, Case Formulation, Treatment Planning, and Clinical Notes.

Joel Yager1,2, Robert E Feinstein2.   

Abstract

Offering a new framework for understanding and studying basic dimensions of normal and abnormal human functioning and mental disorders, the National Institute of Mental Health (NIMH) has initiated the Research Domain Criteria (RDoC) project in which a series of higher order domains, representing major systems of emotion, cognition, motivation, and social behavior, and their constituent operationally defined constructs serve as organizing templates for further research and inquiry, eg, to discover validated biomarkers and endophenotypes. Cutting across traditional DSM diagnoses, the domains are defined as Negative Valence Systems, Positive Valence Systems, Cognitive Systems, Systems for Social Processes, and Arousal/Regulatory Systems. To inform educators, trainees, and practitioners about RDoC, alert them to potential practical applications, and encourage their broad exploration in clinical settings, this article reviews the RDoC domains and their subsystem constructs with regard to potential current clinical considerations and applications. We describe ways in which the RDoC domains and constructs offer transdiagnostic frameworks for complementing traditional practice; suggest clinical questions to help elucidate salient information; and, translating RDoC domains and constructs headings into clinically friendly language, offer a template for the psychiatric review of systems that can serve in clinical notes. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28002661     DOI: 10.4088/JCP.15nr10476

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Should Posttraumatic Stress Be a Disorder or a Specifier? Towards Improved Nosology Within the DSM Categorical Classification System.

Authors:  Jeffrey Guina; Matthew Baker; Kelly Stinson; Jon Maust; Joseph Coles; Pamela Broderick
Journal:  Curr Psychiatry Rep       Date:  2017-08-15       Impact factor: 5.285

Review 2.  Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies.

Authors:  Brisa Solé; Esther Jiménez; Carla Torrent; Maria Reinares; Caterina Del Mar Bonnin; Imma Torres; Cristina Varo; Iria Grande; Elia Valls; Estela Salagre; Jose Sanchez-Moreno; Anabel Martinez-Aran; André F Carvalho; Eduard Vieta
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

Review 3.  Wnt/β-catenin signaling in brain development and mental disorders: keeping TCF7L2 in mind.

Authors:  Joanna Bem; Nikola Brożko; Chaitali Chakraborty; Marcin A Lipiec; Kamil Koziński; Andrzej Nagalski; Łukasz M Szewczyk; Marta B Wiśniewska
Journal:  FEBS Lett       Date:  2019-06-30       Impact factor: 4.124

4.  Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.

Authors:  Andrew Hui
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

5.  A companion to the preclinical common data elements on neurobehavioral comorbidities of epilepsy: a report of the TASK3 behavior working group of the ILAE/AES Joint Translational Task Force.

Authors:  Andrey Mazarati; Nigel C Jones; Aristea S Galanopoulou; Lauren C Harte-Hargrove; Lisa E Kalynchuk; Pierre-Pascal Lenck-Santini; Jesús-Servando Medel-Matus; Astrid Nehlig; Liset Menendez de la Prida; Karine Sarkisova; Jana Veliskova
Journal:  Epilepsia Open       Date:  2018-07-18

Review 6.  [Positive cognitive neuroscience : Positive valence systems of the Research Domain Criteria initiative].

Authors:  Henrik Walter; Anna Daniels; Sarah A Wellan
Journal:  Nervenarzt       Date:  2021-08-10       Impact factor: 1.297

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.